Hello. It's Mark Kris from Memorial Sloan-Kettering, talking today about the American Society of Clinical Oncology Annual Meeting in Chicago, completed a few months ago. I think it was a great meeting and it reminded us of the importance of meeting colleagues face to face, and the ability to network and to learn in person.
I, for one, was overwhelmed by the enormity of the information. It used to be, at least in the lung cancer area, that there was one treatment. Now there are so many treatments and so many nuances. Getting the best information to do that is a formidable task. How to do that is still a work in progress. I think we need to pay attention to how to take what's available, make sure that it gets to the people that can act upon it, and, most importantly, get it to the patients.
The other discussion that came up in that neoadjuvant session was about the use of postoperative radiotherapy. There was a clinical trial a few years ago where there was no significant difference in survival based on receiving postoperative therapy or not, and there was some increased toxicity in patients who received therapy postoperatively because of radiation to the heart.
I think what we really need to do is dive into the specifics of a patient and ask, do these data truly apply to them? The other thing I was struck by is when we improve our adjuvant and neoadjuvant therapies, more and more people are suffering failure in the chest — lung and lymph node disease. Clearly, ways to improve upon that — and irradiation may be one of them — need to have some attention.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ABC7Chicago - 🏆 284. / 63 Read more »
Source: KSLcom - 🏆 549. / 51 Read more »